ArticleTherapeutic advances in gastroenterology2026
Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study.
Yukiya Narita et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.